AllDocs -> cancers

« cancers »
by www.alldocs.info
the most recent document references on :: cancers

Web	cancers.alldocs.info

Languages:

Found 2056 documents Page 15 of 69 Pages: << < 10 11 12 13 14 15 16 17 18 19 20 > >>

cancers

myeloma

homepage

www.alldocs.info

Legenda:

last week

last month

[421] Stem cell Harvesting and High Dose Therapy and Rescue in Myeloma ...

[36,4 KB] From [www.christie.man.ac.uk] Last viewed: 06.07.2006

myeloma 1146 Adult Leukaemia Unit Stem cell Harvesting and High Dose Therapy and Rescue in Myeloma – ESHAP Mobilization What is ESHAP chemotherapy If your myeloma has failed to respond as well as hoped to your first course of treatment you will be offered ESHAP. This will have a positive disease effect and will allow us to collect peripheral blood stem cells from you. ESHAP treatment consists of 4 different drugs: Cytarabine, Cisplatin, Etoposide and a steroid. You will have this treatment as an inpatient over 5 days. As a lot of fluid is involved, you will need a double lumen central line for the treatment. What are stem cells? These are the immature parent cells which live in the bone marrow. From these stem cells all of your red cells, white cells and platelets will grow and develop. These cells can be collected from the peripheral blood ...

[422] MOLECULAR MECHANISMS OF NOVEL THERAPEUTIC APPROACHES FOR MULTIPLE ...

[2672,7 KB] From [www.tufts.edu] Last viewed: 06.07.2006

June 17 th 2005 PRESS RELEASE Macmillan Cancer Nurses Support Myeloma Awareness Week STAFF from Blackpool Victoria Hospital’s Macmillan Windmill Unit will be holding an information stand in the hospital canteen on Wednesday June 22nd as part of Myeloma Awareness week (June 21 st - 28 th ). Myeloma , also known as multiple myeloma , is a relatively rare cancer of the plasma cells. Plasma cells are a type of blood cell found in the bone marrow which help to protect the body against infection and viruses. In Myeloma , one plasma cell becomes faulty and multiplies rapidly. This can damage bone marrow and affect the immune system. Myeloma is not curable at present but treatment can control the effects of the disease. Chemotherapy is usually used although radiotherapy is given to control bone pain. In younger patients, ...

[423] 060597 Multiple Myeloma

[125,6 KB] From [hematology.wustl.edu] Last viewed: 06.07.2006

MEDICAL PROGRESS Volume 336 Number 23 1657 Review Article Medical Progress M ULTIPLE M YELOMA R ÉGIS B ATAILLE , M.D., P H .D., AND J EAN -L UC H AROUSSEAU , M.D. From the Laboratory of Hematology, Institute of Biology (R.B.), and the Department of Clinical Oncology and Hematology (J.-L.H.), Univer- sity Hospital, Nantes, France. Address reprint requests to Dr. Bataille at the Laboratoire d’Hématologie, Institut de Biologie, 9, Quai Moncousu, 44035 Nantes CEDEX 01, France. ©1997, Massachusetts Medical Society. ULTIPLE myeloma is a disorder in which malignant plasma cells accumulate in the bone marrow and produce an immuno- globulin, usually monoclonal IgG or IgA. Common complications of overt multiple myeloma ...

[424] Foundation Drives Research Agenda for Multiple Myeloma

From [jncicancerspectrum.oxfordjournals.org] Last viewed: 06.07.2006

Page 1 of 2 Heidelberg Pharma GmbH Schriesheimer Straße 101 D-68526 Ladenburg Tel +49 (0)6203-1009.0 Fax +49 (0)6203-1009.18 e-mail info@heidelberg-pharma.com Web www.heidelberg-pharma.com Sitz der Gesellschaft Bergheimer Str. 89/1 D-69115 Heidelberg, Amtsgericht Heidelberg HRB 337657 Geschäftsführer Dr. jur. Jan Schmidt-Brand Bankverbindungen Deutsche Bank AG; BLZ: 672 700 03; Kto. 018859900; BW-Bank AG; BLZ 672 700 20; Kto. 5310108500 Apoptosis inducers Heidelberg Pharma (HDP) also develops new APIs based on its proprietary Apotosis In- ducer Program. Apoptosis inducing agents represent a targeted approach for the treat- ment of cancer and autoimmune diseases and may target tumor cells more specifically than conventional chemotherapeutic drugs. Our lead drug candidate in this area, Imexon, entered into a combined clinical phase I/II proof-of-efficacy ...

[425] Chronic Myelogenous Leukemia. Chronic Myeloid Leukemia ...

[3080,7 KB] From [www.newsrx.com] Last viewed: 06.07.2006

MGN-3 AS CONJUNCTIVE THERAPY IN MULTIPLE MYELOMA -ROLE OF ACTIVATED NATURAL KILLER CELLS (CASE REPORT) Mamdooh Ghoneum*, Frank Salem,Department of Otolaryngology1, and Pathology2,C.R. Drew University of Medicine and Science -1621 East 120th Street, Los Angeles, CA 90059 *To whom correspondence should be sent. 1. Clinical History: Patient is a 58 year old male who was diagnosed as having multiple myeloma (M.M.) at October 19, 1990. Clinical symptoms included low back pain and general weakness. Past history revealed no serious illness. 2.Physical Examination: The most significant positive finding of physical examinations was a severe low back tenderness over L-5 S1 area. The remainder of the physical findings were within the normal range. 3. Laboratory Data: 24 h. urine Bence-Jones protein (BJP) 1100mg/daily. Urine protein immunofixation electrophoretic patterns obtained with the use of the antisera ...

[426] First Ever European Network of Myeloma Patient Groups Launched at ...

[88,1 KB] From [www.myeloma-euronet.org] Last viewed: 25.06.2006

PRESS RELEASE First Ever European Network of Myeloma Patient Groups Launched at the 10 th Congress of the European Hematology Association (EHA) in Stockholm The launch of the very first European network of myeloma patient Groups, the MYELOMA EURONET, took place at the 10 th Congress of the European Hematology Association (EHA) in Stockholm on 3 June where they unveiled their new website, www. myeloma -euronet.org. The organisation is an innovative alliance of myeloma patient groups in Europe who are working together on shared goals and objectives to bring benefit to patients and their families living with myeloma . Myeloma is an increasingly common cancer of the plasma cells that is incurable, but treatable, and affects over 31,000 people in Europe at any one time. 1 Anita Waldmann, president of Deutschen Leukämie- und Lymphom-Hilfe e.V. (DLH) ...

[427] smopRthalidomide for treatment of multiple myelomaEMEA-COMP-262-04

[40,5 KB] From [www.emea.eu.int] Last viewed: 25.06.2006

European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40 E-mail: orphandrugs@emea.eu.int www.emea.eu.int EMEA 2005 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged Document Date: London, 11 October 2005 Doc.Ref.: EMEA/COMP/262/2004 COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS PUBLIC SUMMARY OF POSITIVE OPINION FOR ORPHAN DESIGNATION OF thalidomide for the treatment of multiple myeloma On 19 December 2001, orphan designation (EU/3/01/068) was granted by the European Commission to Kendle International Limited, United Kingdom, for thalidomide for the treatment of multiple myeloma . What is multiple myeloma ? Multiple myeloma is a cancer of a type ...

[428] smopRthalidomide for the treatment of multiple myelomaEMEA-COMP-263-04

[40,0 KB] From [www.emea.eu.int] Last viewed: 25.06.2006

European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40 E-mail: orphandrugs@emea.eu.int www.emea.eu.int EMEA 2005 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged Document Date: London, 11 October 2005 Doc.Ref.: EMEA/COMP/263/2004 COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS PUBLIC SUMMARY OF POSITIVE OPINION FOR ORPHAN DESIGNATION OF thalidomide for the treatment of multiple myeloma On 20 November 2001, orphan designation (EU/3/01/067) was granted by the European Commission to Pharmion Ltd, United Kingdom, for thalidomide for the treatment of multiple myeloma . What is multiple myeloma ? Multiple myeloma is a cancer of a type of white blood ...

[429] smopRarsenic trioxide myelomaEMEA-10959-03

[41,6 KB] From [www.emea.eu.int] Last viewed: 25.06.2006

[430] Bortezomib with or without dexamethasone in relapsed multiple ...

[86,2 KB] From [www.haematologica.org] Last viewed: 17.06.2006

[431] Immunoglobulin genes in multiple myeloma: expressed and non ...

[111,8 KB] From [www.haematologica.org] Last viewed: 17.06.2006

[432] 10th Anniversary Multiple Myeloma Research Foundation “Friends for ...

[323,5 KB] From [www.multiplemyeloma.org] Last viewed: 17.06.2006

[433] Focussed Symposia Arsenic trioxide (Trisenox ) in multiple myeloma ...

[3943,0 KB] From [www.haematologica.it] Last viewed: 17.06.2006

[434] TORONTO & DISTRICT MULTIPLE MYELOMA SUPPORT GROUP NEWSLETTER #50

[211,6 KB] From [www.myelomacanada.ca] Last viewed: 17.06.2006